work
describ
design
synthesi
evalu
lowmolecular
weight
peptid
sarscov
proteas
inhibitor
inhibitor
design
base
potent
tripeptid
zvalleuala
k
nm
valin
unit
substitut
varieti
distinct
moieti
result
seri
dipeptidetyp
inhibitor
display
moder
good
inhibitori
activ
pro
particular
compound
exhibit
good
inhibitori
activ
k
valu
mm
respect
lowmolecular
weight
compound
attract
lead
develop
potent
peptidomimet
inhibitor
pharmaceut
profil
dock
studi
perform
model
bind
interact
compound
sarscov
proteas
preliminari
sar
studi
peptidomimet
compound
potent
inhibitori
activ
reveal
sever
structur
featur
boost
inhibitori
activ
benzothiazol
warhead
posit
ii
glactam
unit
iii
appropri
hydrophob
leucin
moieti
iv
hydrogen
bond
narylglycin
unit
backbon
hydrogen
bond
donor
sinc
first
appear
southern
china
late
sever
acut
respiratori
syndrom
sar
recogn
global
threat
rapid
unexpect
spread
countri
affect
individu
caus
nearli
fatal
worldwid
within
month
caus
sar
pathogen
novel
coronaviru
sarscov
sarscov
positivestrand
rna
viru
genom
sequenc
moder
homolog
known
coronavirus
sarscov
encod
chymotrypsinlik
proteas
pro
also
refer
main
proteas
pro
play
pivot
role
process
viral
polyprotein
control
replicas
complex
activ
enzym
indispens
viral
replic
infect
process
make
ideal
target
design
antivir
therapi
pro
activ
site
contain
catalyt
dyad
cystein
residu
act
nucleophil
histidin
residu
act
gener
acid
base
sar
epidem
success
control
howev
potenti
reemerg
pandem
sarscov
continu
pose
risk
new
strain
sar
could
potenti
virul
strain
contribut
outbreak
sinc
two
addit
human
coronavirus
identifi
patient
around
world
recent
new
sarslik
viru
hcovemc
identifi
least
two
individu
one
die
recent
first
case
fatal
respiratori
ill
similar
deadli
sar
confirm
britain
world
health
organ
announc
close
monitor
situat
work
ensur
high
degre
prepared
new
viru
found
suffici
transmiss
caus
commun
outbreak
signific
need
develop
antisar
agent
capabl
treat
potenti
fatal
respiratori
ill
sever
report
crystallin
form
sarscov
pro
protein
bound
hexapeptidyl
chloromethyl
keton
inhibitor
report
numer
peptid
structur
report
context
target
antivir
drug
design
report
proteas
inhibitor
gener
peptid
natur
often
five
three
residu
length
bear
reactiv
warhead
group
cterminu
form
interact
proteas
catalyt
fig
two
compound
recent
describ
separ
report
group
exhibit
excel
potent
inhibitori
activ
k
valu
nm
respect
peptid
inhibitor
provid
valuabl
insight
design
constraint
system
quickli
led
develop
nonpeptid
small
molecul
inhibitor
fig
small
molecular
inhibitor
gener
show
moder
good
activ
recent
perform
structureeact
relationship
studi
base
lead
compound
zvalleuala
studi
led
discoveri
potent
compound
k
valu
low
nanomolar
rang
extend
studi
toward
develop
new
antisar
agent
report
design
synthesi
evalu
seri
lowmolecular
weight
dipeptidetyp
compound
valin
unit
remov
previou
lead
zvalleuala
compound
fig
preliminari
sar
studi
led
identif
inhibitor
moder
good
inhibitori
activ
particular
compound
exhibit
potent
inhibitori
activ
k
valu
mm
respect
bind
interact
predict
use
molecular
model
studi
describ
result
extens
studi
detail
includ
design
synthesi
molecular
model
biolog
evalu
seri
sarscov
pro
inhibitor
synthesi
titl
inhibitor
achiev
coupl
reaction
involv
two
key
fragment
shown
scheme
one
key
fragment
intermedi
use
directli
subsequ
step
glactamthiazol
synthes
use
approach
similar
synthes
report
previous
accordingli
optic
pure
lglutam
acid
ester
convert
glactam
ester
treatment
bromoacetonitril
follow
reduct
pto
cycliz
result
ester
hydrolyz
presenc
naoh
methanol
yield
correspond
acid
coupl
n
odimethylhydroxylamin
via
edcehobt
method
afford
weinreb
amid
weinreb
amid
coupl
appropri
thiazol
presenc
nbutyl
lithium
nbuli
lithium
diisopropylamid
lda
c
afford
glactamthiazol
boc
protect
group
remov
result
intermedi
subsequ
react
abovement
nprotect
amino
acid
presenc
obenzotriazolen
n
n
n
tetramethyluroniumhexafluoro
phosphat
hbtu
dipea
dmf
afford
titl
compound
compound
purifi
revers
phase
hplc
character
h
c
nmr
mass
spectrometri
analysi
puriti
compound
exceed
compound
subject
fluorometr
proteas
inhibitori
assay
sarscov
pro
describ
previous
briefli
kinet
paramet
determin
constant
substrat
concentr
inhibitor
concentr
vari
assess
k
valu
ic
valu
determin
certain
potent
inhibitor
base
appar
decreas
substrat
concentr
hthrseralavalleuglnserglyphearglysnh
upon
digest
sar
pro
describ
previous
cleavag
reaction
monitor
analyt
hplc
cleavag
rate
calcul
decreas
substrat
peak
area
tabl
report
k
ic
valu
mean
independ
experi
effort
develop
lowmolecular
weight
peptid
sarscov
pro
inhibitor
design
seri
dipeptidetyp
inhibitor
base
previou
potent
lead
compound
see
fig
first
attempt
valin
region
remov
cbz
replac
seri
small
moieti
size
similar
valin
group
inhibitori
activ
result
dipeptid
compound
bear
valin
mimic
isopentanoyl
k
mm
tertbutoxi
carbonyl
k
mm
dramat
reduc
compar
activ
k
mm
howev
introduct
cbz
k
ic
mm
moieti
result
activ
increas
respect
although
potenc
reduc
rel
valu
tripeptid
lead
result
suggest
cbz
group
introduc
place
scaffold
dipeptid
convey
appreci
activ
therefor
compound
could
serv
lead
optim
step
retain
cbz
moieti
examin
relev
leucin
residu
isobutyl
unit
substrat
select
comparison
varieti
congen
accordingli
seri
isoster
introduc
includ
nbutyl
k
mm
isopropyl
k
mm
secbutyl
k
mm
thio
ethyl
k
mm
benzyl
k
mm
compound
bear
nbutyl
isopropyl
benzyl
group
exhibit
reason
inhibitori
activ
although
potenc
reduc
factor
rel
valu
inhibitori
activ
compound
bear
secbutyl
thio
ethyl
sever
reduc
compar
activ
therefor
leucin
residu
isobutyl
group
select
appropri
group
provid
enhanc
inhibitori
activ
moieti
lead
compound
examin
introduc
wide
varieti
substitu
aryl
heteroaryl
acetyl
propionyl
arylacrylyl
aryloxyacetyl
narylglycyl
initi
aryl
heteroaryl
acetyl
propionyl
introduc
includ
phenylacetyl
k
mm
k
ic
mm
k
mm
k
mm
among
compound
deriv
exhibit
potent
inhibitori
activ
phenylacetyl
deriv
particular
display
low
inhibitori
activ
therefor
moieti
provid
good
altern
cbz
group
next
introduc
arylacrylyl
includ
cinnamoyl
k
mm
k
mm
k
mm
compound
show
moder
inhibitori
activ
rel
lead
thu
acrylyl
consid
moieti
context
previou
report
describ
sar
studi
tripeptidomimet
see
fig
sar
inhibitor
reveal
introduct
aryloxyacetyl
ntermin
posit
posit
appear
significantli
enhanc
inhibitori
activ
sarscov
pro
therefor
introduc
seri
aryloxyacetyl
includ
phenoxyacetyl
k
ic
mm
k
mm
k
mm
aminophenoxyacetyl
k
mm
group
place
cbz
group
compound
exhibit
compar
activ
howev
deriv
display
reduc
inhibitori
activ
rel
lead
compound
result
suggest
introduct
aryloxyacetyl
group
dipeptid
appreci
improv
inhibitori
activ
pro
also
introduc
sever
narylglycyl
includ
n
glycyl
k
mm
n
glycyl
k
ic
mm
n
glycyl
k
ic
mm
result
studi
reveal
compound
display
rel
potent
inhibitori
activ
compar
lead
compound
bear
n
glycyl
identifi
potent
inhibitor
present
studi
result
suggest
hydrogen
bond
properti
amino
group
narylglycyl
moieti
might
contribut
improv
activ
see
fig
moieti
examin
next
vari
thiazol
inhibitori
activ
compound
illustr
tabl
inhibitor
exhibit
inhibitori
activ
compar
thiazol
gener
exhibit
low
inhibitori
activ
compar
studi
confirm
benzothiazol
unit
suitabl
warhead
group
moieti
bind
mode
compound
pro
simul
use
molecular
dock
program
describ
previous
examin
molecular
dock
potent
activ
compound
comparison
dock
tripeptid
structur
similar
ligand
dock
structur
elucid
previous
xray
crystallographi
pdb
id
sever
minim
process
perform
use
forc
field
model
solvat
environ
surround
inhibitor
molecular
simul
perform
shown
fig
moieti
tripeptid
compound
origin
ligand
interact
region
proteas
interestingli
aminoacetyl
group
n
glycyl
group
mimick
valin
moieti
tripeptidomimet
report
ligand
interact
compound
protein
describ
detail
fig
particularli
notabl
hydrogen
bond
involv
amino
group
enh
n
glycin
backbon
amino
acid
residu
pro
observ
rel
potent
inhibit
inhibitor
present
studi
sarscov
pro
essenti
natur
hydrogen
bond
explor
optim
studi
dipeptidetyp
sarscov
pro
inhibitor
effort
develop
lowmolecular
weight
peptid
antisar
agent
design
synthes
evalu
seri
dipeptidetyp
inhibitor
valin
unit
potent
tripeptidomimet
lead
compound
replac
number
distinct
function
preliminari
studi
compound
bear
benzyloxycarbonyl
cbz
moieti
identifi
lead
compound
moieti
systemat
modifi
view
improv
biolog
activ
studi
led
identif
compound
bear
narylglycyl
moieti
higher
inhibitori
activ
due
presenc
hydrogen
bond
backbon
amino
acid
residu
pro
leucin
benzothiazol
unit
identifi
appropri
moieti
respect
accordingli
compound
recogn
potent
inhibitor
present
studi
potent
dipeptid
inhibitor
provid
attract
lead
undergo
structur
modif
effort
improv
pharmaceut
profil
process
underway
report
near
futur
reagent
solvent
purchas
wako
pure
chemic
ind
ltd
osaka
japan
aldrich
chemic
co
inc
milwauke
wi
use
without
purif
analyt
thinlay
chromatographi
tlc
perform
merck
silica
gel
precoat
plate
prepar
hplc
perform
use
reversephas
column
mm
sunfir
prep
chemic
analyt
grade
better
h
c
nmr
spectra
obtain
use
jeol
mhz
spectromet
varian
mercuri
spectromet
mhz
bruker
spectromet
mhz
tetramethylsilan
intern
standard
highresolut
mass
spectra
esi
ei
record
micromass
qtof
ultima
api
jeol
jmsgcmate
spectromet
mass
spectra
esi
record
shimadzu
synthet
procedur
prepar
tertbutyl
solut
commerci
avail
lleucin
tertbutyl
ester
g
mmol
dmf
ml
ad
isovaler
acid
g
mmol
hobt
h
g
mmol
edc
hcl
g
mmol
result
solut
cool
c
ice
bath
condit
tea
ad
dropwis
min
ice
bath
remov
mixtur
allow
stir
h
ambient
temperatur
dmf
remov
high
vacuum
result
residu
dissolv
etoac
ml
organ
layer
wash
citric
acid
ml
nahco
ml
brine
ml
solut
dri
na
filter
evapor
reduc
pressur
give
compound
result
crude
compound
purifi
silica
gel
column
chromatographi
use
hexaneeetoac
eluent
yield
white
solid
intermedi
prepar
lleucin
tertbutyl
ester
variou
commerci
avail
carboxyl
acid
accord
procedur
describ
synthesi
solut
commerci
avail
lleucin
tertbutyl
ester
g
mmol
ch
cl
ml
ad
benzyloxycarbonyl
chlorid
ml
mmol
result
solut
cool
c
tea
ml
mmol
ad
dropwis
min
ice
bath
remov
mixtur
allow
stir
h
room
temperatur
mixtur
wash
h
ml
brine
ml
yield
lleucin
tertbutyl
ester
colorless
oil
yield
lleucin
tertbutyl
ester
light
pink
solid
procedur
solut
correspond
tertbutyl
ester
g
mmol
ch
cl
ml
c
ad
tfah
ml
min
stir
reaction
mixtur
allow
stir
room
temperatur
h
solvent
complet
evapor
reduc
pressur
give
correspond
acid
use
directli
subsequ
step
without
character
procedur
b
solut
correspond
methyl
ester
g
mmol
thf
ml
room
temperatur
ad
lioh
water
g
mmol
h
stir
solvent
complet
evapor
reduc
pressur
result
residu
neutral
hcl
solut
extract
etoac
ml
dri
na
filter
evapor
reduc
pressur
give
correspond
acid
directli
use
next
step
without
character
compound
prepar
sequenti
reaction
wellknown
intermedi
report
previous
solut
g
mmol
methanol
ml
ad
naoh
solut
mol
room
temperatur
mixtur
stir
h
methanol
evapor
residu
neutral
hcl
extract
etoac
ml
organ
layer
wash
brine
dri
na
evapor
reduc
pressur
yield
correspond
acid
solut
acid
mmol
dmf
ml
ad
edc
hcl
g
mmol
hobt
h
g
mmol
n
odimethylhydroxylamin
g
mmol
ambient
temperatur
solut
cool
c
tea
ml
mmol
ad
slowli
h
dmf
evapor
high
vacuum
result
residu
dissolv
etoac
ml
result
solut
subsequ
wash
citric
acid
ml
nahco
ml
brine
ml
organ
layer
dri
na
concentr
reduc
pressur
yield
weinreb
amid
deriv
purifi
column
chromatographi
etoacmeoh
data
compound
report
previous
solut
benzothiazol
g
mmol
thf
c
ad
nbuli
thf
ml
dropwis
min
h
stir
weinreb
amid
g
mmol
thf
slowli
ad
dropwis
min
solut
stir
h
temperatur
reaction
quench
sat
nh
cl
allow
stir
c
min
mixtur
evapor
dissolv
etoac
solut
wash
water
ml
brine
ml
dri
na
filtrat
organ
layer
concentr
reduc
pressur
result
residu
subject
flash
chromatographi
etoacmeoh
obtain
pure
compound
data
compound
report
previou
articl
cool
solut
commerci
avail
g
mmol
dri
thf
c
slowli
ad
solut
lda
ml
mmol
h
precool
solut
contain
weinreb
amid
g
mmol
anhydr
thf
slowli
ad
reaction
stir
c
h
solut
allow
warm
room
temperatur
quench
addit
water
ml
extract
etoac
ml
combin
organ
layer
dri
anhydr
na
filter
evapor
vacuo
crude
mixtur
purifi
use
flash
chromatographi
nhexaneetoac
furnish
data
compound
report
previous
compound
prepar
accord
procedur
describ
synthesi
data
compound
report
previou
articl
data
compound
report
previou
articl
data
compound
report
previou
articl
solut
g
mmol
ch
cl
ml
c
ad
tfah
ml
solut
stir
h
evapor
solvent
reduc
pressur
correspond
deprotect
lactam
residu
g
mmol
coupl
carboxyl
acid
g
mmol
use
coupl
agent
hbtu
g
mmol
presenc
diisopropylethylamin
ml
mmol
dmf
ml
c
reaction
mixtur
allow
stir
h
ambient
condit
solvent
evapor
high
vacuum
residu
dissolv
etoac
ml
organ
layer
wash
citric
acid
ml
nahco
ml
brine
ml
solut
dri
na
filter
evapor
reduc
pressur
give
compound
yield
light
yellow
solid
compound
prepar
use
procedur
similar
describ
synthesi
yield
colorless
solid
h
nmr
mhz
compound
prepar
use
procedur
similar
describ
synthesi
crystal
structur
sarscov
proteas
complex
substrat
analog
inhibitor
code
obtain
protein
data
bank
pdb
http
wwwrcsborgpdbhom
homedo
initi
bind
model
pro
simul
form
basi
comparison
previou
potent
lead
tripeptidomimet
substrat
analog
use
molecular
oper
environ
moe
softwar
sever
minim
process
perform
use
forc
field
model
solvat
environ
surround
inhibitor
structur
rel
low
bind
free
energi
high
number
cluster
member
select
subsequ
dock
conform
optim
step
minim
energi
obtain
dock
studi
kcalmol
